Cornerstone Q1 net revenues down
The company has reported a net income of $1.74m, or $0.07 per diluted share, compared to net income of $5.01m or $0.19 per diluted share, for the same
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
Almac has implemented biocatalytic technology for metabolite synthesis, isolation and structural identification. Metabolite synthesis is another tool within selectAZyme’s service providing access to both oxidative and glycosylated products.